Overview
- ANMAT authorization and distribution began in late November 2025 for post‑surgery treatment of select melanoma patients in Argentina.
- The therapy is indicated for stages IIB, IIC and IIIA to reduce recurrence risk and is not a preventive vaccine.
- Administration occurs under specialist supervision in authorized oncology centers, with Hospital de Oncología María Curie named as the first site in Buenos Aires.
- Laboratorio Pablo Cassará manufactures the product, which is supplied through high‑cost oncology channels rather than pharmacies, with pricing described as comparable to monoclonal antibodies.
- Clinicians report relatively few general adverse effects and the lead researcher cites non‑recurrence in over 60% of treated patients, while wider real‑world outcomes are still to be determined.